Targeting Interleukin-1 in Heart Disease
نویسندگان
چکیده
منابع مشابه
Targeting interleukin-1 in heart disease.
Targeting Interleukin-1 in Heart Disease Print ISSN: 0009-7322. Online ISSN: 1524-4539 Copyright © 2013 American Heart Association, Inc. All rights reserved. is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231 Circulation doi: 10.1161/CIRCULATIONAHA.113.003199 2013;128:1910-1923 Circulation. http://circ.ahajournals.org/content/128/17/1910 World Wide Web at: ...
متن کاملP 77: The Role of Interleukin-1 in Neurogenesis and Alzheimer Disease
One of the most serious neurodegenerative disorders is Alzheimer disease (AD). As the population is aging and due to the fact that AD is more common in aged people, more attention must be paid to this disease. One of the main characteristics of AD is dementia which starts with loss of short term memory, then progresses and causes various brain dysfunctions such as loss of long term memory. Inte...
متن کاملTargeting calcium transport in ischaemic heart disease.
Ischaemic heart disease (IHD) is the leading cause of morbidity and mortality worldwide. While timely reperfusion of acutely ischaemic myocardium is essential for myocardial salvage, it leads to a unique type of injury known as 'myocardial ischaemia/reperfusion (I/R) injury'. Growing evidence suggests that a defect in myocardial Ca(2+) transport system with cytosolic Ca(2+) overload is a major ...
متن کاملTargeting protein phosphatase 1 in heart failure.
Over the past three decades the treatment of heart failure has shifted from a palliative care approach to a more successful focus on neurohormonal modulation through drugs that inhibit -adrenergic, angiotensin, and aldosterone signaling. Despite these relatively recent advances, the clinical syndrome of heart failure remains progressive in nature. This observation begs the question as to a unif...
متن کاملRationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease.
Erdheim-Chester disease (ECD) pathophysiology remains largely unknown. Its treatment is not codified and usually disappointing. Interferon (IFN)-α therapy lacks efficacy for some life-threatening manifestations and has a poor tolerance profile. Because interleukin (IL)-1Ra synthesis is naturally induced after stimulation by IFN-α, we hypothesized that recombinant IL-1Ra (anakinra) might have so...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Circulation
سال: 2013
ISSN: 0009-7322,1524-4539
DOI: 10.1161/circulationaha.113.003199